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Abstract 
Glioblastoma multiforme, a neoplasm with
variable histological and biological features, is
characterized  by  diverse  imaging  features,
including highly heterogeneous enhancement.
This reflects variable disruption of the blood
brain barrier and inherent differences in the
vascularity of the tumor. Experience in treat-
ing  malignant  glioma  with  antiangiogenic
drugs  is  growing,  and  the  most  commonly
used, in combination with irinotecan or other
cytotoxic agents as salvage therapy, is beva-
cizumab, a monoclonal antibody against vascu-
lar endothelial growth factor.
A  42-year-old,  right-handed  person  with
recurrent  glioblastoma  multiforme  presented
with two synchronous foci of recurrent disease
in follow-up: one area with enhancement and
another  one  nonenhancing  and  infiltrative,
which responded differently to treatment with
bevacizumab  and  irinotecan.  Our  example
demonstrates  the  heterogeneous  nature  of
glioblastoma multiforme and is proof of princi-
ple  for  antiangiogenic  treatment  in  selected
enhancing,  presumably  angiogenic  forms  of
glioblastoma  multiforme.  Antiangiogenic
treatment may be ineffective in more infiltra-
tive, biologically different lesions.
Introduction
Glioblastoma multiforme (GBM) is a neo-
plasm with variable features not only histolog-
ically but also biologically. GBM is character-
ized  by  diverse  imaging  features,  including
highly heterogeneous enhancement, reflecting
variable disruption of the blood brain barrier
(BBB) and inherent differences in the vascu-
larity of the tumor. There is growing experi-
ence with the treatment of malignant glioma
with  antiangiogenic  drugs.  Bevacizumab,  a
monoclonal antibody against vascular endothe-
lial growth factor (VEGF), has been used most
commonly in combination with irinotecan or
other cytotoxic agents as salvage therapy.
Our  case  report  vividly  demonstrates  dis-
parate responses to combined biochemothera-
py in the same patient with recurrent GBM.
Two synchronous foci of recurrent disease, one
area  with  enhancement  and  another  one
nonenhancing and infiltrative, responded dif-
ferently  to  treatment  with  bevacizumab  and
irinotecan. This case illustrates the principle
of antiangiogenesis mechanisms in the treat-
ment of enhancing GBM, and provides a dra-
matic  example  of  the  heterogeneity  of  the
tumor biology and its different responses to
treatment.
Case Report 
A  42-year-old,  right-handed,  previously
healthy man presented with one week of morn-
ing  headaches,  general  weakness,  vertigo,
nausea, and vomiting. His neurological exami-
nation  revealed  a  mild  pronator  drift  of  the
right upper limb, without other abnormalities.
Brain  magnetic  resonance  imaging  (MRI)
showed  an  enhancing  right  frontotemporal
tumor (Figure 1). The patient underwent right
temporal craniotomy for gross total removal of
the tumor. The pathology was typical for GBM,
with nuclear atypia, multiple mitotic divisions,
vascular  endothelial  proliferation,  and  focal
tumor necrosis. 
The patient began standard chemoradiation
(conformal external beam radiation, 200 cGy
per fraction, with concomitant temozolomide
75 mg/m
2 per day). Two weeks into his treat-
ment, he was admitted to the emergency room
with headache, vertigo, and a new left homony-
mous  hemianopsia.  A  brain  computerized
tomography  (CT)  scan  revealed  early  recur-
rence of the tumor with significant vasogenic
edema and midline shift. The patient under-
went a repeat right temporal craniotomy with
gross total removal of the recurrent tumor and
implantation of Gliadel wafers. He was treated
with intravenous antibiotics for postoperative
cerebrospinal fluid leak and meningitis. After
resolution  of  postoperative  complications  he
completed  hypofractionated  radiation  with
concurrent  temozolomide,  and  went  on  to
receive  16  adjuvant  cycles  of  monthly  temo-
zolomide. 
He enjoyed good quality of life throughout
this  period,  with  his  only  symptoms  being
hemianopsia  and  mild  impulsive  behavior.
Brain MRI performed after the sixteenth cycle
of adjuvant chemotherapy showed recurrent,
enhancing,  multifocal  disease  involving  the
right frontoparietal lobes, and nonenhancing
involvement  of  the  contralateral,  left  medial
temporal  lobe  (Figures  2A  and  C).  These
changes were predated by progressive cogni-
tive  decline,  behavioral  changes,  and  gait
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Figure 1. (A) Initial preoperative magnetic resonance imaging (MRI) scan: axial T1-
weighted sequence with gadolinium demonstrates a right temporal, centrally hypointense
lesion with mass effect and midline shift. (B) Axial T1-weighted sequence MRI with
gadolinium following the second operation, postradiation, demonstrates a cystic cavity
with postsurgical changes, resolution of mass effect, and shift. 
ABinstability. The patient was started on a sal-
vage  protocol  of  intravenous  irinotecan  and
bevacizumab, 125 mg/m
2 and 5 mg/kg, respec-
tively, every two weeks. After four treatments
(over two months) his MRI scan showed dra-
matic,  almost  complete  resolution  of  the
enhancing component of his disease (Figure
2B), but further progression of the ill-defined,
nonenhancing, infiltrative, left medial tempo-
ral tumor (Figure 2D). Clinically, he became
progressively  confused,  displayed  dressing
apraxia,  increased  emotional  lability,  impul-
siveness, and loss of insight. A fifth treatment
of biochemotherapy was given with the addi-
tion of carboplatin AUC 5, but the patient con-
tinued to decline clinically, and he was trans-
ferred to hospice, where he died of progressive
disease.
Discussion
The  natural  history  of  recurrent  GBM  is
variable, as the tumor is biologically heteroge-
neous. We are only beginning to understand
the molecular genetic components and distinct
mechanisms that may determine a given neo-
plasm's  behavior  and  response  to  various
treatments.  Recent  studies  have  shown  the
importance of a variety of molecular character-
istics, including methylation of the methylgua-
nine methyltransferase enzyme (MGMT) pro-
moter,
1 epidermal  growth  factor  receptor
(EGFR)  vIII  and  phosphatase  and  tensin
homolog (PTEN) status,
2 and likely, the status
of  VEGF  and  VEGF  receptor
3 in  relation  to
tumor growth and treatment responses. 
Chemotherapy  has  an  important  salvage
role  in  the  treatment  of  recurrent  GBM.
4
Targeting of tumor angiogenesis is a recently
developed method for tumor control and stabi-
lization,  which  shows  promise  in  the  treat-
ment of several tumor types including malig-
nant  glioma.  Biochemotherapy  with  beva-
cizumab  and  cytotoxic  agents  (including
irinotecan) has been shown to improve sur-
vival significantly in patients with non-small-
cell lung cancer and metastatic colorectal can-
cer.
5,6 Use of antiagiogenic agents with chemo-
therapy  has  been  shown  to  be  effective  in
recurrent GBM as well.
7 The initial report by
Stark-Vance using combined bevacizumab and
irinotecan in the treatment of recurrent GBM
demonstrated  an  unprecedented  high
response rate.
8 These findings were supported
in phase II trials of bevacizumab and irinote-
can  in  recurrent  malignant  glioma,
9,10 which
led to FDA approval of bebacizumab for second-
line treatment of recurrent or progressive GBM
in May 2009. A phase II randomized, noncom-
parative clinical trial of bevacizumab alone or
in combination with irinotecan in a group of
167 patients revealed six months of progres-
sion free survival (PFS) of 42.6% and 50.3% in
the bevacizumab arm alone and in combina-
tion  with  irinotecan,  respectively,  with  9.2
months,  with  bevacizumab  alone  and  8.7
months median survival with combined thera-
py.
11 Bokstein, et al.
12 reported a series of 20
patients with recurrent malignant glioma who
were treated with bevacizumab at 5 mg/kg and
irinotecan at 125 mg/m
2. These patients treat-
ed with a lower dose of bevacizumab showed a
six-month  PFS  and  overall  survival  (OS)  of
25% and 55%, respectively, with fewer throm-
boembolic complications.
12
Studies of imaging in combined biochemo-
therapy have shown impressive radiographic
responses.  The  radiological  differences  in
tumor enhancement pattern may be caused by
several factors, among them tumor necrosis,
tumor vascularity, and severity of damage to
the  BBB.
13 Pope,  et  al.
14 assessed  the  early
imaging effects of bevacizumab coupled with
etoposide,  carboplatin,  or  irinotecan  in  a
cohort of 14 patients with recurrent malignant
glioma. An imaging response rate of 50% was
seen.  Several  patients  were  found  to  have
responses  in  areas  of  necrotic-appearing
tumor, whereas solid areas of their tumor con-
tinued to grow. An explanation for this phe-
nomenon might be found in the differences in
requirements of tumor endothelium for VEGF
receptor stimulation in necrotic versus solid
areas of tumor.
14
Our case demonstrates two heterogeneous,
synchronous  GBM  lesions  in  a  patient  with
recurrence; one focus displayed dense contrast
enhancement  while  the  contralateral  lesion
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Figure 2. (A) T1-gadolinium FSPGR magnetic resonance imaging (MRI) scan, revealing a
recurrent right frontoparietal focus before treatments with irinotecan and bevacizumab.
(B) T1-gadolinium FSPGR MRI, post four treatments with irinotecan and bevacizumab
demonstrating almost complete resolution of the enhancing disease. (C) T2 Flair MRI
sequence revealing the medial left temporal nonenhancing focus pre irinotecan and beva-
cizumab treatment. (D) T2 Flair MRI sequence post irinotecan and bevacizumab treat-
ment demonstrating progression of the ill-defined, nonenhancing, infiltrative left medial
temporal lobe disease (despite dramatic response of the right-sided disease as depicted in
B).
AB
CDwas ill-defined and nonenhancing. Following
biochemotherapy  with  irinotecan  and  beva-
cizumab,  the  enhancing  tumor  showed  dra-
matic resolution while the infiltrative, nonen-
hancing lesion progressed and ultimately lead
to  the  demise  of  the  patient.  This  example
demonstrates  the  heterogeneous  nature  of
GBM and is proof of principle for antiangio-
genic  treatment  in  selected  enhancing,  pre-
sumably angiogenic forms of GBM, although
antiangiogenic  treatment  may  be  ineffective
in  more  infiltrative,  biologically  different
lesions.
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